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Fibrillin-1 (FBN1), a major structural component 
of microfibrils in extracellular matrix plays an 
important role in organ development and tis-
sue homeostasis (Sakai et al., 1986; Zhang et al., 
1995). Recent studies show that LTBP-1 (latent 
transforming growth factor- binding protein-1) 
interacts with FBN1 through its pro-domains 
(Charbonneau et al., 2004; Ramirez and Sakai, 
2010). Thus, Fbn1 deficiency increases the level 
of activated TGF- in the intercellular micro-
environment. Clinically, Fbn1 gene mutation is 
linked to several human diseases, including sys-
temic sclerosis (SSc)/scleroderma, Marfan’s syn-
drome, ectopic lentis, and the dominant form 
of Weill-Marchesani syndrome (Lee et al., 1991; 
Charbonneau et al., 2004). These diseases are 
usually characterized by connective tissue fibrosis 
and skeletal disorders, but it is unclear whether 
Fbn1 deficiency contributes to bone disorders 
in these diseases.
As an established SSc mouse model, Fbn1 
partial intragenic duplication mutant tight-skin 
mice (B6.Cg-Fbn1Tsk/J; Fbn1+/) show signifi-
cantly reduced femoral bone mineral density 
(BMD) and altered trabecular microarchitecture 
(Barisic-Dujmovic et al., 2007). Loss of func-
tion of Fbn1 induced a bone disorder involving 
elongated bone length and reduced bone density, 
similar to Marfan syndrome (Dietz et al., 1991, 
1994; Lee et al., 1991; Quarto et al., 2012), 
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Fibrillin-1 (FBN1) deficiency-induced systemic sclerosis is attributed to elevation of  
interleukin-4 (IL4) and TGF-, but the mechanism underlying FBN1 deficiency–associated 
osteopenia is not fully understood. We show that bone marrow mesenchymal stem cells 
(BMMSCs) from FBN1-deficient (Fbn1+/) mice exhibit decreased osteogenic differentia-
tion and increased adipogenic differentiation. Mechanistically, this lineage alteration is 
regulated by IL4/IL4R-mediated activation of mTOR signaling to down-regulate RUNX2 
and up-regulate PPAR2, respectively, via P70 ribosomal S6 protein kinase (P70S6K). 
Additionally, we reveal that activation of TGF-/SMAD3/SP1 signaling results in enhance-
ment of SP1 binding to the IL4R promoter to synergistically activate mTOR pathway in 
Fbn1+/ BMMSCs. Blockage of mTOR signaling by osteoblastic-specific knockout or rapa-
mycin treatment rescues osteopenia phenotype in Fbn1+/ mice by improving osteogenic 
differentiation of BMMSCs. Collectively, this study identifies a previously unrecognized role 
of the FBN1/TGF-/IL4R/mTOR cascade in BMMSC lineage selection and provides experi-
mental evidence that rapamycin treatment may provide an anabolic therapy for osteopenia 
in Fbn1+/ mice.
© 2015 Chen et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/ 
by-nc-sa/3.0/).
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Figure 1. Fbn1-deficient (Fbn1+/) mice exhibit osteopenia phenotype. (A–C) MicroCT (A), BMD (B), and BV/TV (C) analysis of trabecular bone (TB) area in 
WT and Fbn1+/ mouse distal femurs. (D) H&E staining of TB volume (yellow square) in distal femurs of Fbn1+/ mice (n = 15) and WT littermates (n = 10). Bar,  
1 mm. (E) IHC staining of ALP+ osteoblasts in Fbn1+/ mice and WT littermates. (F) TRAP staining of osteoclasts in distal femur trabecular bone (TB) and BM in WT 
and Fbn1+/ mice. Arrowheads, TRAP+ osteoclasts (purple cells). Bar, 25 µm. (G–I) ELISA analysis of serum sRANKL (G), OPG (H), and CTX (I) in Fbn1+/ mice and WT 
littermates. (J) Toluidine blue staining showed the number of CFU-F from WT and Fbn1+/ BMMSCs. (K and N) Alizarin red staining of Fbn1+/ (K) and Fbn1 siRNA 
knockdown (N) BMMSCs showed the capacity to form mineralized nodules when cultured under osteoinductive conditions. (L and O) Western blot analysis of 
Fbn1+/ (L) and Fbn1 siRNA knockdown (O) BMMSCs showed expressed levels of FBN1 and the osteogenic genes RUNX2, ALP, and OCN. -Actin was used as a 
protein loading control. (M and P) Subcutaneous implantation of BMMSCs in immunocompromised mice showed that bone (B), BM, and connective tissue (CT) 
were generated around HA/TCP (HA) at 8 wk after implantation. Bars, 50 µm. A semiquantitative analysis showed the amount of bone formation in BMMSC im-
plants. (Q) Calcein double labeling of the metaphyseal trabecular bone in the distal femora showed the bone turnover rate in WT and Fbn1+/ mice. Bar, 25 µm. All 
experimental data verified in at least three independent experiments. Error bars represent the SD from the mean values. ***, P < 0.005; NS, not significant.
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suggesting that dysregulation of TGF- signaling by Fbn1 
mutation is the major factor underlying this bone deficiency 
(Judge et al., 2004; Dietz et al., 2005; Lemaire et al., 2006). 
Fbn1+/ mice represent an autoimmune connective tissue dis-
order characterized by type 2 helper T cell (TH2 cell) infiltra-
tion and vascular damage (Gabrielli et al., 2009). IL4, a key 
TH2 cytokine plays a critical role in the regulation of fibrotic 
tissue deposition through the signal transducer and activator 
of transcription-6 (STAT6) pathway (Wynn, 2004). Although 
the mechanism that results in an elevated level of IL4 in 
Fbn1+/ mice is unknown, down-regulation of the Il4 gene in 
Fbn1+/ mice can rescue the pathogenesis in fibrotic diseases, 
suggesting that IL4 signaling is associated with fibrotic phe-
notype in SSc (Kodera et al., 2002). However, it is unknown 
whether IL4 signaling contributes to the osteoporotic pheno-
type in SSc mice.
BM mesenchymal stem cells (BMMSCs) constitute a pop-
ulation of self-renewal and multipotent cells that can differen-
tiate into osteoblasts, adipocytes, fibroblasts, chondrocytes and 
nonmesenchymal cell types (Friedenstein et al., 1974; Prockop, 
1997). BMMSCs are a promising cell source for bone regen-
eration and immunoregulatory therapies by interacting with 
several subsets of immune cells (Le Blanc et al., 2004; Uccelli 
et al., 2007; Ren et al., 2008; Sun et al., 2009; Uccelli and 
Mancardi, 2010; Akiyama et al., 2012). In response to stimula-
tion from multiple environmental factors, BMMSCs can dif-
ferentiate into different lineage cells, which are regulated at 
both transcriptional and translational levels (Shi et al., 2002; 
Shi and Gronthos, 2003). In the present study, we show that 
Fbn1 regulates BMMSC osteogenic/adipogenic lineage selec-
tion via IL4R/mTOR (the mammalian target of rapamycin) 
signaling. Blockage of the mTOR cascade by rapamycin, an 
anticancer and immune suppressive drug, ameliorates the os-
teopenia phenotype in Fbn1+/ SSc mice.
RESULTS
Fbn1 deficiency alters BMMSC lineage differentiation
Because Fbn1 gene mutation leads to significant loss of bone 
volume and increase in BM adipocytes in B6.Cg-Fbn1Tsk/J 
(Fbn1+/) mice (Barisic-Dujmovic et al., 2007), we hypothe-
size that Fbn1 deficiency may reduce osteogenic differentiation 
of BMMSCs and elevate their adipogenic differentiation. To 
test this hypothesis, we confirmed that Fbn1 deficiency re-
sulted in an osteopenia phenotype in Fbn1+/ mice. MicroCT 
and histological analysis showed that BMD, bone volume ver-
sus total volume (BV/TV), and distal femoral trabecular bone 
structure of Fbn1+/ mice were markedly decreased compared 
with the WT littermates (Fig. 1, A–D). Histomorphometric 
analysis revealed that the numbers of both osteoblasts and 
osteoclasts in the femur of Fbn1+/ mice were significantly 
reduced in comparison with the WT group by alkaline phos-
phatase (ALP) immunohistochemical (IHC) staining and 
tartrate-resistant acid phosphate (TRAP) staining, respectively 
(Fig. 1, E and F). The level of soluble receptor activator of nu-
clear factor B ligand (sRANKL), but not osteoprotegerin 
(OPG), was significantly reduced (Fig. 1, G and H). In addition, 
we examined the in vivo function of osteoclasts and found 
that the serum type I collagen cross-linked telopeptide (CTX) 
level was significantly decreased in Fbn1+/ mice (Fig. 1 I). 
These data imply that the loss of bone volume in Fbn1+/ 
mice may be mainly associated with an insufficient bone for-
mation. To examine whether Fbn1 deficiency affects the stem 
cell properties of BMMSCs, we isolated BMMSCs (Fig. 2, A–C) 
to show that the number of colony forming unit-fibroblasts 
(CFU-Fs) was significantly reduced and the expression level 
of FBN1 was decreased in Fbn1+/ BMMSCs compared with 
the WT control (Fig. 1, J and L). The osteogenic differentia-
tion capacity of Fbn1+/ BMMSCs was decreased, as indi-
cated by reduced mineralized nodule formation and expression 
of the osteogenic regulators runt-related transcription factor 2 
(RUNX2), ALP, and osteocalcin (OCN; Fig. 1, K and L). 
Using an established in vivo BMMSC implantation assay, in 
which 4 × 106 BMMSCs with carrier hydroxyapatite tricalcium 
phosphate (HA/TCP) particles were subcutaneously implanted 
into immunocompromised mice, we showed that BMMSCs 
derived from Fbn1+/ mice generated less bone structure than 
the WT group at 8 wk after implantation (Fig. 1 M). To fur-
ther confirm the role of Fbn1 in BMMSC differentiation, we 
used siRNA to silence Fbn1 gene expression in BMMSCs 
(Fig. 2 D) and found a significantly reduced osteogenic differ-
entiation, as assessed by alizarin red staining to show reduced 
mineralized nodule formation, immunoblotting analysis to 
show decreased expression of the osteogenic markers RUNX2, 
ALP, and OCN, and in vivo BMMSC implantation assay to 
show reduction in new bone formation (Fig. 1, N–P). To fur-
ther confirm reduced osteogenesis in Fbn1+/ mice, we per-
formed a calcein labeling assay to show that the bone turnover 
rate was decreased in Fbn1+/ mice (Fig. 1 Q). In contrast, Oil 
red O staining showed the number of adipocytes in Fbn1+/ 
BM was markedly increased when compared with the WT lit-
termates (Fig. 2 E). To confirm that Fbn1 deficiency results in 
elevated adipogenesis, Fbn1+/ BMMSCs were found to exhibit 
a significantly elevated number of Oil red O–positive cells 
and up-regulation of the adipogenic regulators peroxisome 
proliferator-activated receptor 2 (PPAR2) and lipoprotein 
lipase (LPL) under adipogenic culture conditions (Fig. 2, 
F and G). Furthermore, we showed that Fbn1-silenced BMMSCs 
by siRNA had a significantly increased number of Oil red 
O–positive cells and up-regulation of PPAR2 and LPL (Fig. 2, 
H and I). These data suggest that Fbn1 governs osteogenic/
adipogenic lineage differentiation in BMMSCs.
Fbn1 modulates BMMSC lineage differentiation  
via IL4R/mTOR signaling
Because previous studies showed that Fbn1 mutation induced 
TH2 infiltration with a high level of IL4 (Gabrielli et al., 2009), 
we used IHC staining and ELISA to confirm a higher number 
of IL4-positive cells in Fbn1+/ mouse BM and an elevated 
IL4 level in the peripheral blood (Fig. 3, A and B). In addition, 
we confirmed that Fbn1+/ mice showed significantly increased 
levels of TH2 cells (Fig. 3, C-F). Quantitative PCR and ELISA 
showed that WT and Fbn1+/ BMMSCs expressed similar 
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showed that Fbn1 deficiency up-regulated IL4R downstream 
signaling phosphoinositide 3-kinase (PI3K)–p110, phospho-
rylated Akt (p-Akt), and phosphorylated mTOR (p-mTOR) 
in Fbn+/ BMMSCs (Fig. 3 J). To verify that IL4R/mTOR 
signaling contributes to BMMSC osteo/adipo-lineage selec-
tion, we examined whether knockdown of the IL4R/mTOR 
cascade could rescue the altered lineage differentiation in 
Fbn1+/ BMMSCs. Having confirmed that shRNAs could 
low levels of IL4 (Fig. 3, G and H). Next, we examined whether 
activation of IL4 downstream signaling contributed to reduced 
osteogenesis and elevated adipogenesis in Fbn1+/ mice. We 
used immunofluorescence staining to confirm that BMMSCs 
coexpressed the MSC marker CD73 with IL4R (Fig. 3 I). 
Compared with control BMMSCs, Fbn1+/ BMMSCs show 
up-regulated expression of IL4R (Fig. 3 J), which was further 
confirmed by qPCR analysis (Fig. 3 K). Western blotting also 
Figure 2. Fbn1-deficient BMMSCs have increased adipo-
genic ability. (A) Flow cytometric analysis showed the surface 
epitope profile of the isolated BMMSCs. (B and C) Alizarin red 
staining and Western blot showed the osteogenic differentiation 
capacities of BMMSCs derived from plastic collected single colo-
nies, CD3 antibody/complement depletion, and flow cytometric 
sorting. (D) Western blot showed the efficacy of Fbn1 siRNAs in 
BMMSCs. (E) Histological images of distal femurs showed the 
number of adipocytes in WT and Fbn1+/ mouse BM, as assessed 
by H&E and Oil red O staining. Bars, 50 µm. (F) The number of Oil 
red O+ cells in WT and Fbn1+/ BMMSCs under adipoinductive 
conditions. Bar, 50 µm. (G) Levels of adipogenic genes PPAR2 
and LPL in WT and Fbn1+/ BMMSCs under adipoinductive con-
ditions. (H) The number of Oil red O+ cells in Fbn1 siRNA knock-
down BMMSCs. Bar, 50 µm. (I) Western blotting showed the 
expression levels of PPAR2 and LPL in Fbn1 siRNA knockdown 
BMMSCs. All experimental data verified in at least three inde-
pendent experiments. Error bars represent the SD from the mean 
values. *, P < 0.05; **, P < 0.001.
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adipogenic differentiation in Fbn1+/ BMMSCs was signifi-
cantly reduced in the shRNAs or rapamycin treatment groups, as 
indicated by a decreased number of Oil red O–positive cells and 
down-regulation of the PPAR2 and LPL (Fig. 4 D). To 
avoid off-target effect, we used IL4R neutralizing antibody 
to block IL4 signaling and found decreased expression of 
p-mTOR and elevated expression of RUNX2 in Fbn1+/ 
BMMSCs when compared with control group (Fig. 4 E). We 
next revealed that mTOR regulated osteogenic differentia-
tion of Fbn1+/ BMMSCs through its downstream signaling 
knock down Il4r and mTOR (Fig. 3 L) and that rapamycin 
treatment could inhibit mTOR signaling in a dose-dependent 
manner (Fig. 3 M), we showed that Il4r and mTOR shR-
NAs, as well as rapamycin treatment, significantly improved 
osteogenic differentiation of Fbn1+/ BMMSCs, as indicated 
by alizarin red staining to show increased mineralized nodule 
formation, Western blotting to show elevated expression of 
the RUNX2, ALP, and OCN, and in vivo BMMSC implan-
tation assay to show increased new bone formation at 8 wk 
after implantation (Fig. 4, A–C). Conversely, the elevated 
Figure 3. TH2/IL4 infiltration in Fbn1-deficient mice. (A) IHC staining of distal femoral in WT and Fbn1+/ mice showed the number of IL4+ cells 
(arrowheads) in BM. Bar, 25 µm. (B) ELISA showed the serum level of IL4 in WT and Fbn1+/ mice. (C–F) Flow cytometry showed TH2 subsets in peripheral 
blood (PB) and BM of WT and Fbn1+/ mice. (G and H) qPCR and ELISA analysis showed the levels of IL4 in WT and Fbn1+/ BMMSCs compared with  
T cells. (I) IF staining showed MSC marker CD73 coexpressed with IL4R in WT and Fbn1+/ BMMSCs. Bar, 25 µm. (J) Western blotting showed expression 
mTOR signaling genes, including IL4R, PI3K-p110, p-Akt, and p-mTOR in WT and Fbn1+/ BMMSCs. (K) qPCR analysis of IL4R in WT and Fbn1+/ 
BMMSCs. (L) Western blot showed efficacy of Il4r and mTOR shRNAs in Fbn1+/ BMMSCs. (M) Western blot showed that rapamycin treatment induced a 
dose-dependent inhibition of p-P70S6K in Fbn1+/ BMMSCs. (N) Western blot showed the expression levels of p-mTOR and p-P70S6K in shRNAs and 
rapamycin-treated Fbn1+/ BMMSCs. Shown are representative of all experimental data verified in at least three independent experiments. Error bars 
represent the SD from the mean values. ***, P < 0.005.
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levels of mTOR was unaffected (Fig. 4 H). To avoid off-target 
effects, a second P70s6k siRNA was used to show elevated 
expression of RUNX2 (Fig. 4 I). In addition, the osteogenic 
differentiation was markedly increased in P70s6k knockdown 
Fbn1+/ BMMSCs, as indicated by elevated mineralized nod-
ule formation (Fig. 4 J) and expression of the RUNX2, ALP, 
and OCN (Fig. 4 K). In contrast, the number of Oil red O–
positive cells (Fig. 4 L) and the expression levels of the adipo-
genic genes were significantly down-regulated (Fig. 4 M), 
phosphorylated P70 ribosomal S6 protein kinase (P70S6K). 
Western blot analysis showed that p-P70S6K expression level 
was increased in Fbn1+/ BMMSCs (Fig. 4 F). When p-mTOR 
expression was knocked down by Il4r and mTOR shRNAs, 
or rapamycin treatment, in Fbn1+/ BMMSCs, a correspond-
ing down-regulation of p-mTOR and p-P70S6K was revealed 
by Western blot analysis (Fig. 3 N). Although knockdown of 
P70s6k expression by siRNA in Fbn1+/ BMMSCs resulted in 
up-regulation of RUNX2 expression (Fig. 4 G), the expression 
Figure 4. Fbn1 deficiency-induced acti-
vation of IL4R/mTOR signaling regulates 
osteogenic/adipogenic lineage differentia-
tion of BMMSCs. (A) Alizarin red staining 
showed the capacity to form mineralized 
nodules in scrambled shRNA (sh-Scr)–treated, 
Il4r, and mTOR shRNA- and rapamycin-
treated Fbn1+/ BMMSCs. (B) Western blot 
showed the expression of the osteogenic 
genes RUNX2, ALP, and OCN in Fbn1+/ 
BMMSCs with shRNAs and rapamycin treat-
ment. (C) H&E staining showed BMMSC- 
mediated bone (B) and BM regeneration when 
subcutaneously implanted into immuno-
compromised mice with HA carrier after  
shRNAs and rapamycin treatment in Fbn1+/ 
BMMSCs. Bars, 50 µm. A semiquantitative 
analysis showed the amount of bone formation 
in different implants. (D) Oil red O staining 
showed the capacity to differentiate into 
adipocytes in shRNAs and rapamycin-treated 
Fbn1+/ BMMSCs, as well as the expression 
levels of adipogenic genes PPAR2 and LPL. 
Bar, 50 µm. (E) IL4R neutralizing antibody 
(NAb) treatment showed the expression levels 
of p-mTOR and RUNX2 in Fbn1+/ BMMSCs. 
(F) Western blot showed the level of  
p-P70S6K in Fbn1+/ BMMSCs. (G) Western 
blot showed the expression level of RUNX2 in 
Fbn1+/ BMMSCs after knockdown of P70s6k 
by siRNA. (H) Western blot analysis showed 
the expression of p-mTOR after knockdown of 
P70s6k. (I) To avoid off-target effects, two 
P70s6k siRNAs were used to show they both 
elevated expression of RUNX2 in Fbn1+/ 
BMMSCs. (J–M) Knockdown of P70s6k by 
siRNA, Fbn1+/ BMMSCs showed increased 
mineralized nodule formation by alizarin red 
staining (J), elevated expression of RUNX2, 
ALP, and OCN (K), decreased Oil red O+ cells 
(bar, 50 µm; L), and decreased expression of 
PPAR2 and LPL (M). All experimental data 
verified in at least three independent experi-
ments. Error bars represent the SD from the 
mean values. ***, P < 0.005; **, P < 0.01.
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O–positive cells and the expression of PPAR2 and LPL (Fig. 5, 
G and H). These data suggest that activation of the IL4/IL4R/
mTOR/P70S6K cascade contributes to osteogenic deficiency 
of Fbn1+/ BMMSCs and that blockade of mTOR signaling 
may be a promising therapeutic approach for rescuing osteo-
genic deficiency in Fbn1+/ mice.
Because mTOR signaling involves two complexes, namely 
mTOR complex 1 (TORC1) and complex 2 (TORC2), we 
next examined which mTOR complex plays a functional 
role in regulating Fbn1+/ BMMSC differentiation. We found 
that Fbn1+/ BMMSCs expressed elevated levels of mTOR/
Raptor/TORC1 and mTOR/Rictor/TORC2 when com-
pared with the control group (Fig. 5 I). When using siRNA 
to knockdown either TORC1 or TORC2, the expression of 
the osteogenic marker Runx2 was up-regulated in Fbn1+/ 
BMMSCs (Fig. 5 J). Knockdown of TORC2 resulted in down- 
regulation of both Raptor and Rictor, whereas knockdown of 
TORC1 only resulted in down-regulation of Raptor (Fig. 5 K), 
suggesting that TORC2 may act upstream of TORC1. To avoid 
off-target effects, we used secondary TORC1 and TORC2 
suggesting that mTOR regulates P70S6K to control RUNX2-
mediated osteogenic differentiation and PPAR2-mediated 
adipogenic differentiation.
To further confirm that the IL4–IL4R pathway activates 
mTOR signaling, we performed a dosage and kinetics analysis to 
show that IL4 at a concentration of 50–100 ng/ml is able to acti-
vate mTOR signaling in WT BMMSCs and the activation of 
mTOR signaling can occur as earlier as 6 h after IL4 treatment 
(Fig. 5, A and B). When treated with IL4, Fbn1+/ BMMSCs ex-
hibited a more significant increase in the expression of p-mTOR 
than the control BMMSCs (Fig. 5 A). Western blot analysis 
confirmed up-regulation of mTOR downstream signaling 
including PI3K, p-Akt, p-mTOR, and p-P70S6K (Fig. 5 C). 
Furthermore, we showed that IL4 treatment–activated mTOR 
signaling inhibited osteogenic differentiation of WT BMMSCs, 
as indicated by reduced mineralized nodule formation, decreased 
expression of the RUNX2, ALP, and OCN, and reduced bone 
formation when subcutaneously implanted into immuno-
compromised mice (Fig. 5, D–F), along with elevated adipogenic 
differentiation, as indicated by the increased number of Oil red 
Figure 5. IL4/mTOR signaling governs 
lineage commitment of BMMSCs.  
(A) Western blot showed that IL4 treatment 
resulted in elevated expression of p-mTOR in 
an dose-dependent manner in WT and 
Fbn1+/ BMMSCs. (B) Western blot showed IL4 
treatment resulted in elevated p-mTOR expres-
sion starting at 6 h after treatment and last-
ing until 72 h after treatment in WT BMMSCs.  
(C) Western blot showed the expression of 
mTOR signaling, including PI3K-p110, p-Akt, 
p-mTOR, and p-P70S6K in IL4-treated 
BMMSCs. (D) Alizarin red staining showed 
BMMSC-mediated mineralized nodule forma-
tion after mTOR activation. (E) Western blot 
indicated the expression of osteogenic genes 
RUNX2, ALP, and OCN in BMMSCs after mTOR 
activation. (F) H&E staining showed the  
capacity to form bone in mTOR-activated 
BMMSCs when implanted into immuno-
compromised mice. Bar, 50 µm. A semiquanti-
tative analysis showed the amount of bone 
formation in implants. (G) Oil red O staining 
showed the number of adipocytes in mTOR-
activated BMMSCs. Bar, 50 µm. (H) Western 
blot showed the expression of adipogenic 
genes PPAR2 and LPL in mTOR-activated 
BMMSCs. (I) Western blot showed the expres-
sion levels of p-Rictor and p-Raptor in Fbn+/ 
BMMSCs. (J) Western blot showed the expres-
sion of osteogenic marker RUNX2 in Fbn1+/ 
BMMSCs after siRNA knockdown of either 
Rictor or Raptor. (K) Western blotting analysis 
showed that knockdown of Rictor resulted in 
down-regulation of both Raptor and Rictor, whereas knockdown of Raptor resulted in only down-regulation of Raptor. (L) To avoid off-target effects, 
second TORC1 or TORC2 siRNAs were used to show elevated expression of RUNX2 in BMMSCs. (M) Western blot showed that knockdown of Rictor, but 
not Raptor, resulted in down-regulation of p-Akt. All experimental data verified in at least three independent experiments. Error bars represent the SD 
from the mean values. ***, P < 0.005.
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neutralizing antibody blocking. Western blot analysis revealed 
that both TGF-1 and Fbn1 siRNA treatment increased IL4R 
levels, which could be blocked by TGF- neutralizing anti-
body treatment (Fig. 6, C–F). To further confirm that TGF- 
signaling activates IL4R expression, we used siRNA to block 
canonical TGF- pathway and then examine the expression 
level of IL4R in Fbn1+/ BMMSCs. Western blot analysis 
showed that IL4R was significantly decreased in Fbn1+/ 
BMMSCs after Smad2/3 siRNA treatment (Fig. 6 G), indi-
cating that TGF-/SMAD3 signaling may directly regulate 
IL4R expression. To determine whether increased expression 
of IL4R in Fbn1+/ BMMSCs is attributed to the TGF-/
SMAD3 signaling, we generated an Il4r promoter reporter 
construct in which the defined region of the Il4r promoter 
and flanking region were placed upstream of a reporter gene 
encoding firefly luciferase. We used BIOBASE biological da-
tabases to search the Il4r promoter sequence and found two 
SP1 and one STAT6 candidate sites, which were closely match-
ing with the SMAD3-associated SP1 and IL4R downstream 
STAT6 transcription factors consensus targets (Fig. 6 H). We 
next demonstrated that Il4r promoter activity was markedly 
induced in both Fbn1+/ and TGF-–treated BMMSCs. When 
Fbn1+/ BMMSCs were transfected with reporter vector, the 
luciferase assay showed a significantly increased Il4r promoter 
siRNAs to show they are able to elevate expression of RUNX2 
in Fbn1+/ BMMSCs (Fig. 5 L). Because Akt is a downstream 
target of TORC2, we examined the expression levels of p-Akt 
after the knockdown of either TORC1 or TORC2 and con-
firmed that TORC2 acted upstream of TORC1 through the 
Akt cascade in Fbn1+/ BMMSCs (Fig. 5 M).
IL4R is activated by the TGF- pathway  
in Fbn1-deficient BMMSCs
It was reported that FBN1 interacts with LTBP-1 to bind 
TGF- (Charbonneau et al., 2004; Ramirez and Sakai, 2010). 
As such, Fbn1 deficiency causes an increased release of TGF- 
to the skin and lung (Gabrielli et al., 2009; Holm et al., 2011). 
We examined the level of TGF- in Fbn1+/ mouse BM and 
Fbn1+/ BMMSC culture medium and found that both BM 
and medium contained elevated levels of TGF-, as assessed 
by ELISA assay (Fig. 6 A). Next, we used Western blotting to 
confirm that TGF- downstream signaling p-SMAD3 and 
SMAD-associated transcription factor SP1 (Docagne et al., 2004; 
Jungert et al., 2006) were significantly increased in Fbn1+/ 
BMMSCs compared with the control BMMSCs (Fig. 6 B). To 
further confirm that Fbn1 deficiency-mediated IL4R expres-
sion occurs through TGF- release, we treated BMMSCs with 
recombinant TGF-1 or Fbn1 siRNA, followed by TGF- 
Figure 6. TGF- and STAT6 synergisti-
cally enhance the expression of IL4R in 
Fbn+/ BMMSCs. (A) ELISA assay showed the 
level of TGF- in Fbn1+/ mouse serum and 
Fbn1+/ BMMSCs cultured medium compared 
with WT group. (B) Western blotting showed 
the expression levels of p-SMAD3 and SP-1 in 
WT and Fbn1+/ BMMSCs. (C and D) Western 
blotting showed that TGF- treatment el-
evated IL4R expression in BMMSCs, which 
could be blocked by TGF- neutralizing anti-
body (NAb). (E and F) Western blot showed 
that Fbn1 knockdown by siRNA in BMMSCs 
elevated IL4R expression, which could be 
blocked by TGF- NAb. (G) Western blot 
showed the expression of IL4R after 
Smad2/3 siRNA treatment compared with 
vehicle-treated group. (H) Il4r promoter 
luciferase fusions were examined in WT, TGF-
–treated, and Fbn1+/ BMMSCs. Promoter 
activity was expressed as relative light units 
(RLU) normalized to the activity of cotrans-
fected Renilla luciferase. (I) ChIP-qPCR assay 
showed enrichment of direct association of 
SP1 and STAT6 on Il4r promoter in TGF- 
–treated and Fbn1+/ BMMSCs. (J) Western 
blot showed the expression of p-JAK1 and  
p-STAT6 in Fbn1+/ BMMSCs. (K and L) Western 
blotting showed the expression of IL4R and 
p-mTOR after TGF-, IL4, or combinatorial 
treatment with TGF- and IL4. All experimen-
tal data verified in at least three independent 
experiments. Error bars represent the SD from 
the mean values. ***, P < 0.005.
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cascades (Fig. 6 H). We next determined whether SP1 regulates 
Il4r promoter in BMMSCs. Using chromatin immuno-
precipitation (ChIP), the SP1 binding consensus sequence within 
the promoter region was examined to confirm its ability to 
activity. Introduction of SP1 mutated reporter vector mark-
edly diminished the expression of the Il4r-luciferase reporter 
in both Fbn1+/ and TGF-–treated BMMSCs, indicating the 
direct initiation of IL4R expression by TGF-–SMAD3–SP1 
Figure 7. Conditional KO of IL4R in BMMSC ameliorates osteopenia phenotype by rescuing impaired osteogenic/adipogenic differentia-
tion. (A) Experimental outline describing the use of Il4rf/f crossed with Fbn1+/ mice to generate Il4rf/+;Fbn1+/ mice. Prrx1-Cre mice were crossed with 
Il4r/ mice to generate Prrx1-Cre;Il4r+/ mice. Il4rf/+;Fbn1+/ mice were then crossed with Prrx1-Cre;Il4r+/ mice to generate Il4rf/-;Fbn1+/ (DKO, 
n = 9) and Prrx1-Cre;Il4rf/-;Fbn1+/ (TKO, n = 7) conditional KO mice. Il4r f/ littermates (n = 15) were used as control. (B) qPCR analysis showed the 
efficacy of Cre-medicated deletion of the floxed allele. (C) MicroCT analysis showed the BMD of DKO and TKO mice. Bar, 1 mm. (D) H&E (bar, 1 mm) and 
Oil red O (bar, 50 µm) staining showed the TB volume and percentage of adipocytes in distal femur. (E) Alizarin red staining showed the mineralized nod-
ule forming capacity in Adenovirus-Cre–treated BMMSCs derived from DKO mice (Ad-Cre) compared with Adenovirus-GFP–treated DKO group (Ad-GFP). 
(F) Western blot analysis showed the expression of p-mTOR, RUNX2, ALP, and OCN in Ad-Cre compared with Ad-GFP. (G) Western blot showed the ex-
pression of RUNX2 in IL4R NAb-treated DKO BMMSCs. (H) When implanted into immunocompromised mice subcutaneously with HA carrier, Ad-Cre 
showed significantly increased bone formation. Bar, 50 µm. (I) Oil red O staining showed the number of adipocytes in Ad-Cre. Bar, 50 µm. (J) Western 
blotting showed the expression of adipogenic genes PPAR2 and LPL in Ad-Cre. All experimental data verified in at least three independent experiments. 
Error bars represent the SD from the mean values. ***, P < 0.005.
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expression at the transcriptional level using a promoter re-
porter assay. Control BMMSCs, TGF-–treated BMMSCs, 
and Fbn1+/ BMMSCs were transfected with a reporter vector 
or STAT6 candidate site mutated reporter vector, followed by 
luciferase assay. TGF-–treated and Fbn1+/ BMMSCs showed 
increased promoter activity in comparison to control BMMSCs. 
Introduction of STAT6 mutated reporter vector markedly 
diminished the expression of the Il4r-luciferase reporter in 
Fbn1+/ BMMSCs, but not TGF-–treated BMMSCs. Thus, 
TGF- may act as an initiator to elevate IL4R expression, 
and TGF-–activated IL4R is independent from IL4R-
STAT6 cascades (Fig. 6 H). These results prompted us to 
recruit SP1. As expected, SP1-bound DNA at the candidate 
site was significantly enriched in TGF-–treated BMMSCs and 
Fbn1+/ BMMSCs (Fig. 6 I), suggesting that TGF- may act 
as an initiator to elevate IL4R expression. In parallel, we used 
a ChIP-qPCR assay and found that STAT6 directly bound to 
the predicted promoter region of Il4r and that STAT6 re-
cruitment was enriched at the Il4r promoter in Fbn1+/ or 
TGF-–treated BMMSCs (Fig. 6 I). Western blot analysis 
further confirmed that an IL4R-JAK1-STAT6 cascade was 
activated in Fbn1+/ BMMSCs, as shown by up-regulation of 
p-JAK1 and p-STAT6 expression (Fig. 6 J). These results 
prompted us to examine whether STAT6 induced IL4R 
Figure 8. Conditional KO of mTOR in BMMSC ameliorates osteopenia phenotype by rescuing impaired osteogenic/adipogenic differentiation.  
(A) Experimental outline describing the generation of Mtorf/+;Fbn1+/ (DKO, n = 8) and Prrx1-Cre;Mtorf/+;Fbn1+/ (TKO, n = 6) mice. (B) qPCR analysis showed 
the efficacy of Cre-medicated deletion of the floxed allele. (C) MicroCT analysis showed the BMD of DKO and TKO mice. Bar, 1 mm. (D) H&E (bar, 1 mm) and 
Oil red O (bar, 50 µm) staining showed the TB volume and adipocytes in distal femur of DKO and TKO mice. (E) Alizarin red staining showed the mineralized 
nodule formation in Ad-Cre. (F) Western blotting showed the expression levels of p-mTOR, RUNX2, ALP, and OCN in Ad-Cre and Ad-GFP. (G) When implanted 
into immunocompromised mice with HA carrier, Ad-Cre showed significantly increased bone formation. Bar, 50 µm. (H) Quantitative analysis showed the 
number of Oil red O+ cells in Ad-Cre. Bar, 50 µm. (I) Western blotting showed the expression of adipogenic genes PPAR2 and LPL in Ad-Cre compared with 
Ad-GFP. All experimental data verified in at least three independent experiments. Error bars represent the SD from the mean values. ***, P < 0.005.
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littermates were used as osteopenia models (Fig. 8 A). The ef-
ficacy of Cre-medicated deletion of floxed allele was shown by 
qPCR analysis (Fig. 8 B). MicroCT analysis showed that Mtor 
conditional KO rescued BMD in Fbn1 deficiency–induced os-
teopenia (Fig. 8 C). Histological analysis showed that trabecu-
lar bone volume in TKO mice was increased compared with 
the DKO mice (Fig. 8 D). The numbers of adipocytes in TKO 
mouse BM were significantly reduced when compared with 
the DKO mice, as assessed by Oil red O staining (Fig. 8 D). To 
investigate the role of mTOR in the differentiation of Fbn1 
deficient BMMSCs, we isolated BMMSCs from DKO mice 
and knocked down Mtor using an adenovirus expressing Cre 
with GFP or an adenovirus expressing GFP only as a control. 
Ad-Cre-DKO-BMMSCs showed significantly increased os-
teogenic differentiation, as assessed by alizarin red staining in-
dicating elevated mineralized nodule formation (Fig. 8 E); 
Western blot analysis indicating rescued expression of the os-
teogenic cascade genes RUNX2, ALP, and OCN (Fig. 8 F); 
and in vivo implantation indicating elevated bone formation 
capacity compared with the Ad-GFP-DKO-BMMSCs (Fig. 8 G). 
In contrast, Ad-Cre-DKO-BMMSCs showed a significant de-
crease in adipogenic differentiation compared with Ad-GFP- 
DKO-BMMSCs, as shown by a decreased number of Oil red 
O–positive cells and down-regulation of the adipogenic genes 
PPAR2 and LPL (Fig. 8, H and I).
It has been shown that SP7-expressing osteoblastic pro-
genitors have the ability to control osteoblastic/adipogenic lin-
eage switch (Zhang et al., 2011; Song et al., 2012). To examine 
whether knocking down mTOR signaling in the preosteo-
blastic stage can recover the lineage alteration and osteopenia 
phenotype in Fbn1+/ mice, we generated a tissue-specific KO, 
SP7-Cre;Mtorf/+;Fbn1+/ (TKO) conditional Mtor KO mice 
(Fig. 9 A). Floxed Mtor littermates (Mtor f/+) were used as nor-
mal control and Mtorf/+;Fbn1+/ (DKO) littermates were used 
as osteopenia models (Fig. 9 A). The efficacy of Cre-medicated 
deletion of floxed allele was shown by qPCR analysis (Fig. 9 B). 
MicroCT analysis and histological analyses showed that TKO 
mice have significantly increased BMD and trabecular bone 
volume compared with DKO mice (Fig. 9 C), suggesting that 
Mtor conditional KO in the preosteoblastic lineage rescued os-
teopenia in Fbn1-deficient mice. The number of adipocytes in 
TKO mouse BM was significantly reduced when compared 
with the DKO mice, as assessed by Oil red O staining (Fig. 9 C). 
These data prompted us to use a drug, specifically rapamycin, to 
attempt to ameliorate the disease phenotype in Fbn1+/ mice.
Next, we examined whether rapamycin treatment rescued 
the osteopenia phenotype in Fbn1+/ mice. Rapamycin was 
intraperitoneally administered to Fbn1+/ mice at 8 or 6 wk of 
age for 14 or 28 consecutive days, respectively. The samples 
were harvested at 10 wk of age for further evaluation (Fig. 10 A). 
Histological and microCT analysis showed that rapamycin 
treatment elevated BMD and trabecular bone volume in 
Fbn1+/ mice (Fig. 10 B). The number of adipocytes in BM 
of rapamycin-treated Fbn1+/ mice was significantly reduced 
when compared with untreated Fbn1+/ mouse BM, as assessed 
by Oil red O staining (Fig. 10 B). BMMSCs isolated from 
examine whether TGF- and IL4 synergistically activate the 
mTOR signaling in BMMSCs. We found that TGF-, but 
not IL4, treatment elevated the expression levels of IL4R in 
BMMSCs by Western blot analysis (Fig. 6, K and L). Al-
though TGF- and IL4 treatments each elevated expression 
levels of p-mTOR in BMMSCs, combinatorial treatment of 
TGF- and IL4 resulted in a marked increase in p-mTOR 
expression (Fig. 6, K and L). These results indicate that the 
Fbn1 deficiency-induced TGF-–SMAD3–SP1/IL4R cas-
cade synergistically enhances mTOR signaling with STAT6 
signaling in Fbn1+/ BMMSCs at the transcriptional level, 
which leads to lineage alteration of Fbn1+/ BMMSC.
Conditional knockdown of IL4R/mTOR  
in BMMSCs/osteoblasts or rapamycin treatment  
ameliorates osteopenia phenotype in Fbn1+/ mice
Because IL4R/mTOR alters BMMSC lineage commitment, 
depletion of mTOR expression in BMMSC lineage may serve 
as a key approach to recover Fbn1 deficiency-induced osteo-
penia. To achieve such a tissue-specific KO, we first generated 
Prrx1-Cre;Il4rf/-;Fbn1+/ triple conditional KO (TKO) mice 
to KO IL4R in Fbn1+/ BMMSCs (Fig. 7 A). Il4rf/ lit-
termates were used as normal control, and Il4rf/;Fbn1+/ 
(DKO) littermates were used as osteopenia models (Fig. 7 A). 
The efficacy of Cre-medicated deletion of floxed alleles was 
shown by qPCR analysis (Fig. 7 B). MicroCT analysis showed 
that TKO mice have significantly increased BMD compared 
with DKO mice, indicating that Il4r conditional KO res-
cued BMD in Fbn1 deficiency–induced osteopenia (Fig. 7 C). 
Histological analysis showed that trabecular bone volume in 
TKO mice was increased compared with the DKO mice 
(Fig. 7 D). The numbers of adipocytes in TKO mouse BM 
were significantly reduced when compared with the DKO mice, 
as assessed by Oil red O staining (Fig. 7 D). To investigate the 
role of IL4R in the differentiation of Fbn1+/ BMMSCs, we 
isolated BMMSCs from DKO mice and knocked down Il4r 
using an adenovirus expressing Cre with GFP (Ad-Cre-DKO- 
BMMSCs) or an adenovirus expressing GFP only (Ad-GFP-
DKO-BMMSCs) as a control. Ad-Cre-DKO-BMMSCs showed 
significantly increased osteogenic differentiation, as assessed by 
alizarin red staining indicating elevated mineralized nodule 
formation (Fig. 7 E); Western blotting indicating rescued ex-
pression of the mTOR/osteogenic cascade genes p-mTOR, 
RUNX2, ALP, and OCN (Fig. 7 F); and in vivo implantation 
indicating elevated bone formation capacity compared with 
the Ad-GFP-DKO-BMMSCs (Fig. 7 H). To avoid off-target 
effect, we used IL4R neutralizing antibody to block IL4 sig-
naling and found elevated expression of RUNX2 in DKO 
BMMSCs (Fig. 7 G). In contrast, Ad-Cre-DKO-BMMSCs 
showed a significant decrease in adipogenic differentiation com-
pared with Ad-GFP-DKO-BMMSCs, as shown by a decreased 
number of Oil red O–positive cells and down-regulation of 
the adipogenic genes PPAR2 and LPL (Fig. 7, I and J).
We next generated Prrx1-Cre;Mtorf/+;Fbn1+/ TKO mice 
to KO mTOR in Fbn1+/ BMMSCs (Fig. 8 A). Mtorf/+ litter-
mates were used as normal control, and Mtor f/+;Fbn1+/ (DKO) 
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Mutation of the fibrillin gene causes SSc and Marfan’s syndrome, 
in which bone and connective tissue disorders are observed. 
The bone defects in SSc patients were considered to be an in-
significant clinical symptom; however, recent emerging evi-
dence shows that bone resorption may be a common clinical 
manifestation (Atteritano et al., 2013; Kilic et al., 2013; Omair 
et al., 2013). In the present study, we identified a marked osteo-
penia phenotype in Fbn1 mutant-induced SSc mice. Recently, 
it was suggested that FBN1 and FBN2 might differentially reg-
ulate endogenous BMP and TGF- activity in osteoblasts to 
affect bone growth and development (Nistala et al., 2010). In 
this study, we reveal that Fbn1 deficiency results in an increased 
level of TGF- in BM, which, in turn, initiates a cascade in 
which IL4R is up-regulated in BMMSCs via SMAD3/SP1 
binding to Il4r promoter, leading, as a consequence, to the ac-
tivation of mTOR-P70S6K signaling to directly suppress os-
teogenesis via RUNX2 and promote adipogenesis via PPAR2, 
respectively. Osteogenic differentiation deficiency in Fbn1+/ 
BMMSCs may contribute to an osteoporotic phenotype, such 
as low BMD or reduced trabecular bone structure, in Fbn1+/ 
SSc mice. However, inhibition of mTOR signaling using 
rapamycin-treated Fbn1+/ mice showed significantly increased 
CFU-F number compared with the untreated group (Fig. 10 C). 
Osteogenic differentiation of BMMSCs from rapamycin-treated 
Fbn1+/ mice was markedly improved when compared with 
the untreated Fbn1+/ BMMSCs, as analyzed by alizarin red 
staining to show elevated mineralized nodule formation and 
Western blot analysis to show decreased expression of p-mTOR 
and p-P70S6K and increased expression of the RUNX2, ALP, 
and OCN (Fig. 10, D and E). In contrast, BMMSCs isolated 
from rapamycin-treated Fbn1+/ mice showed a significant 
decrease in adipogenic differentiation compared with the un-
treated Fbn1+/ BMMSCs, as shown by decreased number of 
Oil red O–positive cells and down-regulation of the PPAR2 
and LPL (Fig. 10, F and G).
DISCUSSION
FBN1 is essential for the formation of elastic fibers or micro-
fibrils that provide strength and flexibility to connective tissue. 
Normally, FBN1 is abundant in the connective tissue of 
the aorta, ligature of the human eye lens, bones, and lungs. 
Figure 9. Conditional KO of mTOR in preosteoblastic  
lineage ameliorates osteopenia phenotype. (A) Experimental 
outline describing the generation of Mtorf/+;Fbn1+/ (DKO, n = 6) 
and Sp7-Cre;Mtorf/+;Fbn1+/ (TKO, n = 6) mice. (B) qPCR analysis 
showed the efficacy of Cre-medicated deletion of the floxed 
allele. (C) MicroCT (bar, 1 mm), H&E (bar, 1 mm), and Oil red O 
(bar, 50 µm) staining showed BMD, TB volume, and the number 
of adipocytes in distal femur of DKO and TKO mice. All experi-
mental data verified in at least three independent experiments. 
Error bars represent the SD from the mean values. ***, P < 0.005.
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(Lee et al., 2010b; Martin et al., 2010) osteogenesis, depend-
ing on cell type or differentiation stages. Recently, it has been 
reported that bone matrix secretes IGF-1 (insulin-like growth 
factor-1) to recruit normal BMMSCs for bone remodeling by 
activating mTOR signaling (Xian et al., 2012), indicating that 
mTOR may contribute to the activation of different sets of bio-
logical regulatory controls under certain conditions. In this study, 
we reveal that elevated IL4R expression leads to the activation 
of mTOR-P70S6K signaling in Fbn1+/ BMMSCs, which di-
rectly inhibits the osteogenic gene RUNX2 and suppresses bone 
regeneration in vitro and in vivo. In contrast, rapamycin represses 
rapamycin treatment appears to be a promising approach to 
rescue osteoporotic disorders in the SSc mice.
It is known that mTOR signaling positively regulates ex-
pression of the adipogenic gene PPAR2, which is critical for 
adipogenesis of BMMSCs (Kim and Chen, 2004; Yu et al., 
2008; Zhang et al., 2009). However, controversial findings 
were reported regarding mTOR signaling in osteogenesis in 
that mTOR may be required for osteoblast proliferation, which 
is involved in several signaling pathways through IL6 (Kozawa 
et al., 2001; Takai et al., 2007; Takai et al., 2008). In contrast, 
rapamycin may either inhibit (Shoba and Lee, 2003) or stimulate 
Figure 10. Rapamycin treatment ameliorates 
osteopenia phenotype by rescuing impaired  
osteogenic/adipogenic differentiation of BMMSCs 
in Fbn1+/ mice. (A) Experimental outline describing 
the use of rapamycin to treat Fbn1+/ mice (n = 6 per 
group). (B) MicroCT, H&E (bar, 1 mm), and Oil red O 
(bar, 50 µm) staining showed BMD, TB volume, and 
adipocytes in distal femur of Fbn1+/ mice after rapa-
mycin treatment. (C) CFU-F number of BMMSCs iso-
lated from rapa-treated Fbn1+/ mice compared with 
Fbn1+/ mice. (D) Alizarin red staining showed the 
mineralized nodule forming capacity in BMMSCs 
from rapa-treated Fbn+/ mice. (E) Western blot showed 
the expression levels of p-mTOR, p-P70S6K, RUNX2, 
ALP, and OCN in BMMSCs from rapa-treated Fbn1+/ 
mice. (F) Oil red O staining showed the number of 
adipocytes in rapa-treated Fbn1+/ BMMSCs. Bar,  
50 m. (G) Western blot showed the expression levels 
of PPAR2 and LPL in rapa-treated Fbn1+/BMMSCs. 
All experimental data verified in at least three inde-
pendent experiments. Error bars represent the SD 
from the mean values. ***, P < 0.005.
86 IL4R/mTOR signaling in commitment of Fbn1+/ MSCs | Chen et al.
osteoblastic progenitor stages (SP7-Cre). Previous studies 
showed that SP7-expressing osteoblastic progenitors have the 
ability to control the osteoblastic/adipogenic lineage switch 
(Zhang et al., 2011; Song et al., 2012) and that SP7 can be 
regulated by small microRNA (Zhang et al., 2011). Our data 
showed that SP7-Cre–mediated KO of IL4R/mTOR cascades 
can rescue the BMMSC lineage alteration and osteopenia phe-
notype in Fbn1+/ mice. These data may encourage us to use 
a drug such as rapamycin to ameliorate the disease phenotype 
in Fbn1+/ mice. Rapamycin, a specific mTOR inhibitor, is 
a novel nonsteroidal anticancer and immunosuppressive drug 
(Abraham and Wiederrecht, 1996; Wang et al., 2003; Shaw 
et al., 2004). Several preclinical studies showed that rapamycin 
is effective in treating autoimmune diseases, such as systemic 
lupus erythematosus and rheumatoid arthritis (Yoon, 2009; 
Islander et al., 2011). These diseases are usually associated with 
bone disorders (Weinstein, 2010). Although efficacy of rapa-
mycin treatment in SSc patients must be assessed in clinical 
studies, phase I clinical trials showed optimal safety for its use 
in treating scleroderma patients (Su et al., 2009). Added exper-
imental evidence showed that rapamycin treatment resulted 
in a significant improvement of skin phenotype with regula-
tion of immune index, such as reducing the levels of IL4 and 
IL17 in Fbn1+/ mice (Yoshizaki et al., 2010). These data sug-
gest that the underlying mechanism of rapamycin-mediated 
treatment may be associated with immunomodulation, lead-
ing to the down-regulation of TH2 cells (Lee et al., 2010a). 
Up-regulation of osteogenesis and down-regulation of adipo-
genesis in rapamycin-treated Fbn1+/ mice via inhibition of 
mTOR signaling in BMMSCs may help to rebuild functional 
osteoblasts to improve niche microenvironment for immune 
cells and rebuild homeostasis for the immune system. Because 
of the extensive functional roles of rapamycin in immune, 
anticancer, and osteoporosis therapies, it is necessary to explore 
detailed mechanisms by which rapamycin may target several 
signaling pathways simultaneously.
MATERIALS AND METHODS
Animals. Female C57BL/6J, B6.Cg-Fbn1Tsk/J, B6.Cg-Tg(Prrx1-cre)1Cjt/J, 
B6.Cg-Tg (Sp7-tTA, tetO-EGFP/cre)1Amc/J, and B6.129S4-Mtortm1.2koz/J 
mice were purchased from The Jackson Laboratory and maintained in C57BL/6J 
background in at least 10 backcrosses. Age-matched female littermates were 
used in all experiments. Female immunocompromised nude mice (Beige nu/nu 
XIDIII) were purchased from Harlan. IL4R null (Il4r/) and floxed 
(Il4r/; Herbert et al., 2004) mice were gifts from F. Brombacher (Univer-
sity of Cape Town, Cape Town, South Africa). To generate tissue-specific 
Cre-mediated KO models, Cre-, floxed-, and Fbn1+/ mice were inter-
crossed, and age-matched female littermates were used as WT controls. All 
animal experiments were performed under the institutionally approved pro-
tocols for the use of animal research (University of Southern California 
protocol numbers 11141, 11953, and 11327).
MicroCT analysis. Femurs were harvested and analyzed by Inveon micro-
CT system (Siemens AG). Cross-sectional volumetric BMD was measured at 
right femur mid-diaphysis with a density phantom. Using 3-dimensional 
images, a region of interest in secondary spongiosa was manually drawn near 
the endocortical surface, and BV/TV was assessed as a cancellous bone mor-
phometric parameter.
mTOR/P70S6K signaling, which results in rescuing BMMSC 
deficiency and ameliorating the osteoporotic phenotype in 
Fbn1+/ mice, implicating that IL4R/mTOR is, in fact, a 
major signaling pathway contributing to the osteopenia phe-
notype in Fbn1+/ mice. mTORC1 controls multiple cellular 
regulation processes, such as protein synthesis, cell prolifera-
tion, metabolism, and autophagy (Huang and Fingar, 2014). It 
is possible that activation of the mTORC1 pathway increases 
biosynthetic activity to improve osteogenesis rather than de-
crease bone formation. Thus, the mechanistic details may not 
totally explain the phenotype and further study is required to 
explore the detailed relationship between the mechanism and 
the phenotype. Because Fbn1/ mice are embryonic lethal, we 
cannot examine whether Fbn1 null shows a phenotype similar 
to that observed in Fbn1-deficient conditions.
TH2 cells are a major source of IL4 production in SSc 
(Kodera et al., 2002; Gabrielli et al., 2009). Fbn1+/ mice show 
TH2 infiltration and high levels of IL4. Disruption of IL4 can 
rescue the fibrotic phenotype, suggesting that a high level of 
IL4 may also play a critical role in the disease pathogenesis 
(Kodera et al., 2002; Wynn, 2004; Gabrielli et al., 2009). Recent 
studies show that TGF- contributes to the fibrotic phenotype 
in SSc through activation of extracellular matrix protein ex-
pression, suggesting that TGF- and IL4 signaling may syn-
ergistically activate downstream targets to induce fibrosis in 
SSc (Varga and Abraham, 2007; Gabrielli et al., 2009; Gerber 
et al., 2013). Although overproduction of IL4 can induce os-
teoporotic phenotype in mice (Lewis et al., 1993), activation of 
IL4R may inhibit osteoblast proliferation (Frost et al., 2001), 
indicating that IL4 may affect BMMSC function. Conversely, 
it was reported that local delivery of IL4, using a gene therapy 
approach, prevented bone erosion in arthritis animal models via 
abrogation of osteoclastogenesis (Lubberts et al., 2000; Woods 
et al., 2001; Saidenberg-Kermanac’h et al., 2004). These find-
ings indicate that elevated IL4 caused by Fbn1 deficiency may 
contribute to a low osteoblast/osteoclast turnover rate, as ob-
served in Fbn1+/ mice. It was reported that TGF- stimulates 
osteoclastogenesis via the TAK1–NF-B pathway (Mizukami 
et al., 2002; Gingery et al., 2008). IL4 is a potent inhibitor of 
osteoclastogenesis that operates through various mechanisms, 
such as rapid suppression of NFATc1 expression (Wei et al., 
2002; Cheng et al., 2011) and reduction of RANKL expres-
sion (Fujii et al., 2012) via activation of the STAT6 pathway. 
Our results showed that Prrx1-Cre–mediated knockdown of 
IL4R rescued the osteopenia phenotype and altered BMMSC 
lineage differentiation in Fbn1+/ mice; however, elevated 
serum TGF- levels were unchanged. Therefore, IL4 signaling 
may play a critical role in determining osteoclastogenesis in 
Fbn1+/ mice. Our data also suggest that IL4/IL4R signal-
ing activates mTOR signaling in Fbn1+/ BMMSCs, which 
alters BMMSC osteogenic/adipogenic lineage differentiation, 
as a consequence of reduced osteogenesis and elevated adipo-
genesis in BM.
The lineage switch between osteoblasts and adipocytes 
may be regulated by multiple mechanisms, including at least 
IL4R/mTOR signaling at the early BMMSC (Prrx1-Cre) and 
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cells were removed, and attached cells were cultured for 16 d in -MEM 
(Invitrogen) supplemented with 20% FBS, 2 mM l-glutamine (Invitrogen), 
55 µM 2-mercaptoethanol (Invitrogen), 100 U/ml penicillin, and 100 µg/ml 
streptomycin (Invitrogen). These plastic attached single colonies were pas-
saged with frequent medium changes to eliminate potential hematopoietic 
cells contamination (Soleimani and Nadri, 2009; Zhu et al., 2010). Flow cy-
tometric analysis was performed to show a surface epitope profile of isolated 
BMMSCs (Fig. 2 A). To further confirm that the single colony-derived plastic 
adherent BMMSCs were not contaminated with hematopoietic cells, we 
depleted T cells in BMMSC culture using CD3 antibody treatment. In brief, 
1 ml CD3 antibody was added to 107 BMMSCs and the mixture was incu-
bated at 4°C for 30 min. The cells were centrifuged for 5 min to remove 
unbound antibody, resuspended in 1 ml diluted (1:6) rabbit complement (Pel- 
Freez Biologicals) and incubated at 37°C for 30 min. Subsequently, CD3 
antibody/complement treatment was repeated once (Gilmore et al., 1986). 
In addition, we sorted BMMSCs from BM cells according to their MSC-specific 
surface markers using flow cytometry, as reported previously (Houlihan et al., 
2012). BM cells were selected by lineage markers (Lin) and then sorted by 
PDGFR and Sca-1 (PS). Alizarin Red staining and Western blot analysis 
showed that BMMSCs derived from plastic collected single colonies, CD3 
antibody/complement depletion, and flow cytometric sorting had similar 
osteogenic abilities (Fig. 2, B and C). For CFU-F assay, 106 ANCs from BM 
were seeded in T25 cell culture flasks (Corning). After 16 d, the cultures 
were washed by PBS and stained with 1% toluidine blue solution with 2% 
paraformaldehyde. The cell clusters with more than 50 cells were counted as 
colonies under microscopy.
Osteogenic differentiation assay. BMMSCs were cultured under osteo-
genic culture condition, containing 2 mM -glycerophosphate (Sigma-Aldrich), 
100 µM l-ascorbic acid 2-phosphate (Wako), and 10 nM dexamethasone 
(Sigma-Aldrich) in the growth medium. After 3 wk induction, 1% Alizarin 
Red S (Sigma-Aldrich) staining was performed to detect matrix mineraliza-
tion, and the stained areas were quantified by ImageJ software and shown as 
a percentage of the total area.
Western immunoblotting. Cells were lysed in M-PER mammalian protein 
extraction reagent (Thermo Fisher Scientific) with protease and phosphatase 
inhibitors (Roche), and proteins were quantified using protein concentra-
tion assay (Bio-Rad Laboratories). 20 µg of proteins were separated by SDS-
PAGE and transferred to 0.2 µm nitrocellulose membranes (Millipore). The 
membranes were blocked with 5% nonfat dry milk and 0.1% Tween-20 for 
1 h, followed by incubation overnight with the primary antibodies diluted in 
blocking solution according to manufacturer’s instructions. Antibodies to 
mouse ALP, LPL, PPAR2, IL4R, PI3K-p110, phosphor-SMAD2/3, and 
SP1 were purchased from Santa Cruz Biotechnology, Inc. Antibodies to 
human RUNX2, ALP, and OCN were purchased from Santa Cruz Biotech-
nology, Inc. Antibodies to phosphor-mTOR (Ser2448), mTOR, phospho-Akt 
(Ser473), Akt, phosphor-P70S6K (T389; S371), phosphor-Rictor, phosphor- 
Raptor, and SMAD2/3 were obtained from Cell Signaling Technology. 
Antibodies to mouse RUNX2, FBN1, OCN, and -actin were purchased 
from Abcam, GeneTex, Millipore, and Sigma-Aldrich. The membranes 
were then incubated for 1 h in HRP-conjugated secondary antibody 
(Santa Cruz Biotechnology, Inc.) diluted at 1:10,000 in blocking solution. 
Immunoreactive proteins were detected using SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Fisher Scientific) and BioMax film 
(Kodak). The intensity of bands was measured by using ImageJ software 
and normalized to -actin.
Adipogenic differentiation. For adipogenic induction, 500 nM isobutyl-
methylxanthine (Sigma-Aldrich), 60 µM indomethacin (Sigma-Aldrich), 
500 nM hydrocortisone (Sigma-Aldrich), 10 µg/ml insulin (Sigma-Aldrich), 
and 100 nM l-ascorbic acid phosphate were added into the growth medium. 
After 7 d, the cultured cells were stained with Oil red O (Sigma-Aldrich), 
and positive cells were quantified under microscopy and shown as a number 
to total cells.
In vivo BMMSC implantation assay. Approximately 4.0 × 106 BMMSCs 
were mixed with HA/TCP ceramic powders (40 mg; Zimmer Inc.) and subcu-
taneously implanted into 8-wk-old immunocompromised mice (Gronthos et al., 
2000). At 8 wk after implantation, the transplants were harvested, fixed in 4% 
PFA, and decalcified with 5% EDTA, pH 7.4, followed by paraffin embedding. 
The 6-µm paraffin sections were stained with H&E chemical staining. Total 
BV/TV was quantified by ImageJ software (National Institutes of Health).
In vivo Oil red O staining. To assess the adipose tissue in trabecular areas, 
femurs were fixed in 4% paraformaldehyde and decalcified with 5% EDTA, 
pH 7.4, followed by cryosection. Sections were stained with Oil Red O, and 
positive areas were quantified under microscopy and shown as a percentage 
of total areas.
In vivo rapamycin treatment. Rapamycin (LC Laboratories) was in the 
vehicle containing 0.2% sodium carboxymethylcellulose (Sigma-Aldrich) 
and 0.25% polysorbate 80 (Sigma-Aldrich). Rapamycin with vehicle was in-
traperitoneally administered to Fbn1-deficient mice at a dose of 1.5 mg/kg/d 
for 14 and 28 d, respectively (Blazar et al., 1994). The disease group and 
control mice were treated with vehicle only. Treatment was started at age 
6 or 8 wk, and all groups of mice were healthy.
Histology. To assess trabecular bone and BM areas, femurs were fixed in 
4% paraformaldehyde (Sigma-Aldrich) and then decalcified with 5% EDTA, 
pH 7.4, followed by paraffin embedding. Paraffin sections (6 µm) were 
stained with hematoxylin and eosin (H&E) and analyzed by ImageJ software. 
To perform immunohistochemistry staining, the paraffin-embedded sections 
were blocked with serum matched to secondary antibodies, incubated with 
the ALP or IL4 specific antibodies (1:400; Santa Cruz Biotechnology, Inc.) 
at 4°C for overnight, and then stained using VECTASTAIN UNIVERSAL 
elite ABC kit and ImmPACT VIP Peroxidase Substrate kit (Vector Labora-
tories) according to the manufacturer’s instruction. To quantify osteoclast 
activity, mature osteoclasts were determined by TRAP-positive cells on the 
bone surface. Deparaffinized sections were refixed with a mixture of 50% 
ethanol and 50% acetone for 10 min. TRAP staining solutions (1.6% naph-
thol AS-BI phosphate in N, N-dimethylformamide, 0.14% fast red-violet LB 
diazonium salt, 0.097% tartaric acid, and 0.04% MgCl2 in 0.2 M sodium ac-
etate buffer at pH 5.0) were freshly made. The sections were incubated in 
the solution for 10 min at 37°C under shield and counterstained with tolu-
idine blue. All reagents for TRAP staining were purchased from Sigma- 
Aldrich. To label the mineralization fronts, the mice were given subcutaneous 
injections of calcein (15 mg/kg body weight; Sigma-Aldrich) in 2% sodium 
bicarbonate solution 10 and 3 d before sacrifice. Bone dynamic histomor-
phometric analyses for MAR, MS/BS, and BFR/BS were performed ac-
cording to the standardized nomenclature for bone histomorphometry 
(Parfitt et al., 1987).
ELISA. Peripheral blood serum and cell culture medium were collected, 
and sRANKL, OPG, IL4, and TGF- protein levels were analyzed using 
mouse ELISA Ready-SET-GO kits (eBioscience), according to the manu-
facturer’s instructions. CTX levels were analyzed with a mouse C-telopeptide 
of type I collagen ELISA kit (Novateinbio), according to the manufacturer’s 
instructions. Human IL4 and TGF- protein levels were analyzed using 
ELISA Ready-SET-GO kits (eBioscience), according to the manufacturer’s 
instructions. Human sRANKL protein levels were analyzed using sRANKL 
Super X ELISA kit (Antigenix America Inc.) and OPG levels were analyzed 
by OPG instant ELISA kit (eBioscience), according to the manufacturer’s 
instructions. For measurement of anti-dsDNA antibodies and ANA, periph-
eral blood serum samples were collected from all experimental mice and ana-
lyzed by commercially available ELISA kits (Alpha Diagnostics) according to 
the manufacturer’s instructions.
Isolation of mouse BMMSCs. Single suspension of BM-derived all-nuclear 
cells (ANCs; 15 × 106) from femurs and tibias was seeded into 100 mm culture 
dishes (Corning) and cultured at 37°C with 5% CO2. After 2 d, nonadherent 
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protease inhibitor cocktail and gently scraped from the plate. Cell lysis and 
ChIP were performed using the ChIP Assay kit (Millipore). For chromatin 
fragmentation, cells were sonicated using a Branson Sonifier 450 on power 
setting 4 in 30-s bursts with 1 min cooling on ice for a total sonication time of 
4 min. For immunoprecipitations, 1:100 dilution of SP1 antibody was used to 
capture protein–DNA complexes, and isotype-matched IgG was used as nega-
tive control. All resulting precipitated DNA samples were quantified with 
real-time PCR and expressed as the percentage of input DNA.
Statistics. All experimental group sizes were chosen to ensure adequate sta-
tistical power despite the highly variable nature of the studies performed. No 
animal excluded, and animals were randomly assigned groups for the studies. 
All experiments were not performed in a blinded fashion. Data were assessed 
for normal distribution and similar variance between groups. Comparisons 
between two groups were analyzed by independent unpaired two-tailed 
Student’s t test, and the comparisons between more than two groups were 
analyzed by one-way ANOVA with the Bonferroni adjustment. The p-values 
<0.05 were considered statistically significant.
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